Skip Navigation

DRUG RECORD

 

IPILIMUMAB

OVERVIEW
Ipilimumab

 

Introduction

Ipilimumab is a human monoclonal antibody to cytotoxic T lymphocyte antigen-4 which increases immune reactivity and is used to treat metastatic malignant melanoma.  Ipilimumab has major side effects, many of which can be serious and life threatening including acute liver injury.

 

Background

Ipilimumab (ip” i lim’ ue mab) is a human recombinant monoclonal immunoglobulin G1 antibody to the cytotoxic T lymphocyte antigen-4 (CTLA-4) which is used in cancer immunotherapy.  The CTLA-4 antigen is an important check-point molecule that modulates and down regulates T cell responses.  Inhibition of CTLA on the surface of activated T cells prevents its binding to the costimulatory factor B7, which allows for a continued activation and proliferation of T cells.  The subsequent enhancement of cytotoxic reactivity may play a beneficial role in cancer immunotherapy and can break immunological tolerance.  In several large multicenter studies, ipilimumab therapy resulted in a prolongation of survival in patients with advanced, metastatic or unresectable malignant melanoma, and a proportion of patients had a long term remission.  Ipilimumab was approved for use in advanced melanoma in the United States in 2009 and is under active investigation in several other forms of cancer, including breast, colon, renal cell and pancreatic cancer.  Ipilimumab is available in liquid solution in 50 and 200 mg vials (5 mg/mL) under the brand name Yervoy.  The typical regimen is 3 mg/kg as an intravenous infusion every 3 weeks for a total of four doses.  Side effects are common and can be severe, life threatening and even fatal.  As many as 70% of treated patients develop immune related side effects as a result of immune enhancement including enterocolitis, dermatitis, endocrinopathy, neuropathy, nephritis and hepatitis.  Most of these reactions respond to immunosuppressive therapy.  Early recognition and prompt management of these side effects is an integral component of proper use of ipilimumab.

 

Hepatotoxicity

Mild-to-moderate serum aminotransferase elevations are not uncommon (~10%) during ipilimumab therapy, but are usually self-limited and resolve even with continuing cyclic therapy.  Serum ALT elevations above 5 times the upper limit of normal (ULN) occur in 0.5% to 1.5% of patients, and a proportion of these individuals develop clinically apparent liver injury that can be severe.  The onset of injury is usually after 2 to 4 cycles, 3 to 9 weeks after initiation of treatment.  The pattern of enzyme elevation is most frequently hepatocellular, but can be mixed, particularly at the onset of injury.  Liver histology demonstrates an acute hepatitis-like pattern with focal or confluent necrosis and prominent lymphocytic infiltrates of activated T cells, which is compatible with an immune mediated hepatic injury.  However, autoantibodies are usually not present.  Restarting ipilimumab can result in recurrence of injury, although corticosteroid treatment may block recurrence.

The effects of anti-CTLA-4 inhibition on hepatitis B have not been reported, as enrollment criteria in the clinical trials of ipilimumab have usually excluded patients with hepatitis B or C or preexisting liver disease.  However, it is likely that anti-CTLA-4 treatment would exacerbate chronic hepatitis B and C by enhancing T cell cytotoxicity to viral antigens.

 

Mechanism of Injury

The mechanism of liver injury due to ipilimumab is likely to be immunologically mediated and some cases have appeared to respond to corticosteroid or immunosuppressive therapy, allowing for continuation of ipilimumab therapy.

 

Outcome and Management

Guidelines for management of patients receiving ipilimumab recommend corticosteroids for patients who develop serum aminotransferase elevations above 5 times the ULN, initiating therapy with high doses of intravenous methylprednisolone and switching to oral prednisone after 1 to 2 days, continuing tapering doses for at least 30 days.  Most cases of hepatitis due to ipilimumab resolve with prompt institution of immunosuppressive therapy.  The few fatal cases that have been reported occurred in patients who had other severe immune related adverse events (Stevens Johnson syndrome, capillary leak syndrome) or who had a delay in starting corticosteroid therapy.  Restarting ipilimumab after severe liver injury requiring corticosteroid therapy is usually promptly followed by recurrence of liver injury and is not recommended.

 

Drug Class:  Antineoplastic Agents, Monoclonal Antibodies

 

Top of page


CASE REPORT
Ipilimumab

 

Case 1.  Clinically apparent, acute liver injury due to ipilimumab.
[Modified from Case 5 in: Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci 2012; 57: 2233-40. PubMed Citation]

 

A 43 year old man with metastatic melanoma developed erythema, rash and elevations in serum enzymes 3 days after a third infusion of ipilimumab.  He had no history of liver disease, and all liver tests had been normal before starting ipilimumab therapy.  Serum ALT was 173 U/L (4 times ULN) and Alk P 131 (1.1 times ULN), while bilirubin levels were normal.  The absolute eosinophil count was raised (889/µL) and antinuclear antibody was reactive (2.4 by ELISA), but smooth muscle antibody was not present, and immunoglobulin levels were normal.  Over the next few days, liver tests worsened with ALT rising to 2860 U/L, Alk P 410 U/L and total bilirubin 2.2 mg/dL.  A liver biopsy showed an acute hepatitis superimposed upon fatty liver disease with steatosis, slight ballooning degeneration, occasional Mallory bodies and slight fibrosis.  Initiation of oral prednisone therapy was followed by a slow improvement in enzymes, which fell into the normal range approximately 5 months after onset.  Prednisone was later stopped without recurrence of liver injury.  He died of progressive metastatic melanoma one year later.


Key Points

Medication:Ipilimumab
Pattern: Mixed initially (R=3.7), hepatocellular at peak (R=20.2)
Severity:1+ (symptoms and liver enzyme elevations without frank jaundice)
Latency:6 weeks
Recovery:5 months
Other medications:None mentioned

Comment

The clinical presentation 10 days after a third infusion of ipilimumab and approximately 90 days after starting therapy was typical of the hepatic injury from this monoclonal antibody.  Despite discontinuing further infusions, the liver injury worsened and was eventually treated with low doses of corticosteroids, with a slow but eventually complete response.

 

Top of page


 

REPRESENTATIVE TRADE NAMES
Ipilimumab – Yervoy®

 

DRUG CLASS
Antineoplastic Agents

 

COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

 

Top of page


DRUG CAS REGISTRY NO. MOLECULAR FORMULA STRUCTURE
Ipilimumab 477202-00-9 Monoclonal Antibody Not Available

Top of page


REFERENCES
Ipilimumab

 

References updated: 18 June 2015

  1. Zimmerman HJ. Drugs used to treat rheumatic and musculospastic disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 517-54.  (Expert review of hepatotoxicity published in 1999; well before the availability of most monoclonal antibody therapies).

  2. Reuben A. Biological immunosuppressives. Hepatotoxicity of immunosuppressive drugs. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 580-2.  (Review of hepatotoxicity of immunosuppressive agents mentions that "the biological immunosuppressants are largely free from hepatotoxicity, with the exception of the TNF alpha antagonists"; ipilimumab not specifically discussed).

  3. Chabner BA, Barnes J, Neal J, Olson E, Mujagiv H, Sequist L, Wilson W, et al. Targeted therapies: tyrosine kinase inhibitors, monoclonal antibodies, and cytokines. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1731-53.  (Textbook of pharmacology and therapeutics).

  4. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100: 8372-7. PubMed Citation  (Initial study of anti-CTLA-4 therapy in 14 patients with melanoma, 6 of whom developed clinically apparent immune adverse reactions, including one with hepatitis arising after the third infusion [ALT 6820 U/L], resolving over the ensuing 4 months with corticosteroid therapy: Case 1).

  5. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21: 1712-7. PubMed Citation  (In a clinical trial of ipilimumab in 155 patients with metastatic melanoma, 109 patients [70%] suffered an immune related adverse event, including 14 [9%] with a liver related event, 2 of which were severe and 1 fatal).

  6. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23. PubMed Citation  (Controlled trial of ipilimumab vs a glycoprotein-100 vaccine vs both in 676 patients with metastatic melanoma from 125 centers in 13 countries found ipilimumab therapy prolonged median survival from 6.4 to 10.0 months, but that adverse events were common and usually immune mediated; ALT elevations [>5 times ULN] occurred in 0.5-0.8% of ipilimumab treated patients, but in none of controls).

  7. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37: 499-507. PubMed Citation  (Review of immune related adverse events including hepatitis associated with ipilimumab therapy; recommends stopping therapy for grade 3 toxicity [ALT >5 times ULN] and initiating corticosteroids for at least 30 days).

  8. Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26. PubMed Citation  (Trial of ipilimumab and dacarbazine vs dacarbazine alone in 502 patients with metastatic melanoma found ALT elevations in 33% on the combination vs 6% on dacarbazine alone, and ALT values above 5 times ULN in 16% vs 0.7%, but no deaths due to liver failure).

  9. Ipilimumab (Yervoy) for metastatic melanoma. Med Lett Drugs Ther 2011; 53 (1367): 51-2. PubMed Citation  (Concise review of the pharmacology, efficacy and safety of ipilimumab as therapy of metastatic melanoma shortly after its approval in the US; common side effects are diarrhea, nausea, fatigue, pruritus, rash and colitis; immune related side effects can include hepatitis; cost of a single dose averages $30,000).

  10. Chmiel KD, Suan D, Liddle C, Nankivell B, Ibrahim R, Bautista C, Thompson J, Fulcher D, Kefford R. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 2011; 29: e237-40. PubMed Citation  (61 year old man with melanoma developed fever and rash 10 days after a second dose of ipilimumab [bilirubin 1.2 mg/dL, ALT 2521 U/L, Alk P 275 U/L, ANA negative], rapidly improving on high doses of methylprednisolone, but relapsing when dose was reduced [bilirubin peak 3.8, ALT 6362 U/L], ultimately responding to addition of antithymocyte globulin and mycophenylate).

  11. Hanaizi Z, van Zwieten-Boot B, Calvo G, Lopez AS, van Dartel M, Camarero J, Abadie E, Pignatti F. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 2012; 48: 237-42. PubMed Citation  (Summary of safety and efficacy results of ipilimumab forming the basis of approval in Europe; ALT elevations were reported to occur in only 1-2% of patients, with onset of hepatic injury [which can be fatal] after 3 to 9 weeks).

  12. Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci 2012; 57: 2233-40. PubMed Citation  (Clinical and histological features of 5 patients with liver injury due to ipilimumab; 3 men and 2 women, ages 43 to 76 years, arising after 2 to 4 courses, 39-71 days after initial dose [peak bilirubin 1.5-5.1 mg/dL, ALT 326-3070 U/L, Alk P 206-427 U/L], only one had autoantibodies, resolving with immunosuppressive therapy within 1-4 months; one had recurrence on rechallenge; liver biopsies showed acute hepatitis usually with prominent inflammation, interface hepatitis and confluent necrosis: Case 1).

  13. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691-7. PubMed Citation  (Review of the immune related adverse events associated with ipilimumab therapy and their management mentions that hepatotoxicity occurs in 3-9% of patients, usually with asymptomatic increases in ALT and bilirubin, but some with symptoms; authors recommend use of high doses of corticosteroids for 2 days followed by tapering doses to at least 30 days, multiple courses may be necessary and ipilimumab should not be restarted).

  14. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18: 2039-47. PubMed Citation  (Among 177 patients with metastatic melanoma treated with ipilimumab, 33 had a long term objective response and 15 a complete response).

  15. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the Ipilimumab Network. PLoS One 2013; 8: e53745. PubMed Citation  (Retrospective review of adverse reactions seen in 752 patients with metastatic melanoma treated with ipilimumab in 19 major cancer centers in Europe; 120 events were summarized including 11 involving the liver, which usually presented 3-6 weeks after starting therapy, with marked elevations in serum enzymes; one fatal case described in detail).

  16. Anderson L, Bhatia V. Ipilimumab immune-related adverse reactions: a case report. S D Med 2013; 66 (8): 315-7. PubMed Citation  (Abstract: a case of autoimmune hypophysitis during ipilimumab therapy).

  17. Kim KW, Ramaiya NH, Krajewski KM, Jagannathan JP, Tirumani SH, Srivastava A, Ibrahim N. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 2013; 31: 1071-7. PubMed Citation  (Six patients with ipilimumab hepatitis, ages 44-82 years, five men and one woman, treated with 2-4 cycles presenting with fatigue, fever and nausea [bilirubin 0.5-19.6 mg/dL, ALT 168-975 U/L], resolving within 34-147 days of stopping, many were treated with corticosteroids).

  18. Minter S, Willner I, Shirai K. Ipilimumab-induced hepatitis C viral suppression. J Clin Oncol 2013; 31: e307-8. PubMed Citation  (42 year old man with melanoma and chronic hepatitis C was treated with four courses of ipilimumab and had improvements in serum ALT [192 U/L to normal] and HCV RNA levels [398,938 to <12 IU/mL] during therapy that was partially sustained thereafter [ALT 39 U/L, HCV RNA 1558 IU/mL]).

  19. Bernardo SG, Moskalenko M, Pan M, Shah S, Sidhu HK, Sicular S, Harcharik S, et al. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res 2013; 23: 47-54. PubMed Citation  (Among 11 patients with malignant melanoma treated with ipilimumab, 6 [54%] developed some degree of ALT elevation after 1 to 4 courses, but only one had values above 5 times ULN and all resolved with temporary delay in therapy).

  20. Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS; MDX010-20 Investigators. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013; 119: 1675-82. PubMed Citation  (In clinical trials of ipilimumab in 676 patients with melanoma, immune related adverse events occurred in ~60% of patients arising 3-9 weeks after starting and often mild, but severe in 12% and fatal in 1%, including one case of acute liver failure).

  21. Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013; 18: 733-43. PubMed Citation  (Thorough review of side effects of ipilimumab therapy of melanoma states that common adverse events include fatigue, nausea, vomiting, diarrhea, fever, headache, dizziness, rash and pruritus occurring in 70-88% of patients, and that hepatotoxicity occurs in 2-9% that can be self-limited, but also can be severe and require corticosteroid therapy).

  22. McDermott D, Haanen J, Chen TT, Lorigan P, O'Day S; MDX010-20 Investigators. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol 2013; 24: 2694-8. PubMed Citation  (Among 676 patients with melanoma enrolled in the phase III trial of ipilimumab, 94 [20%] survived for 2 years and 42 [16%] for 3 years; late onset immune related adverse events occurred in 11 patients [14%], but were usually mild and none were hepatic).

  23. Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, Del Vecchio M, et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 2014; 12: 116. PubMed Citation  (Among 855 patients with melanoma treated with ipilimumab in an expanded access program, 19 [2%] developed "liver toxicity", which led to stopping therapy in 1 patient and death from hepatitis in another).

  24. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette
    GP, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006-17. PubMed Citation(Trial of ipilimumab with or without nivolumab in 142 patients with melanoma found higher rates of response but also side effects with the antibody combination, ALT elevations occurring in 22.3% vs 4.3% and values above 5 times ULN in 10.5% vs 0%, but there were no deaths from liver injury).

  25. Zimmer L, Vaubel J, Mohr P, Hauschild A, Utikal J, Simon J, Garbe C, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. PLoS One 2015; 10 (3): e0118564. PubMed Citation  (Among 53 patients with metastatic uveal melanoma treated with ipilimumab, response rates were poor and side effects were common, ALT elevations occurred in 7% and were above 5 times ULN in 4%).

  26. Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, Leming P, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 2014; 312: 1744-53. PubMed Citation  (Among 245 patients with metastatic melanoma treated with ipilimumab with or without sargramostim [GM-CSF] found improved objective responses with the combination and lower rates of severe adverse events, ALT elevations above 5 times ULN occurring in 5.1% vs 5.8% of patients).

  27. Ravi S, Spencer K, Ruisi M, Ibrahim N, Luke JJ, Thompson JA, Shirai K, et al. Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. J Immunother Cancer 2014; 2: 33. PubMed Citation  (Among 9 patients with metastatic melanoma and either chronic hepatitis C [n=4] or B [n=5] treated with ipilimumab, viral levels and serum ALT levels did not change in a consistent manner; most with hepatitis B were on antiviral prophylaxis).

Top of page

 

OTHER REFERENCE LINKS
Ipilimumab
  1. PubMed logoRecent References on Ipilimumab

  2. Clinical Trials logoTrials on Ipilimumab

Top of page